From an earlier thread on ACE-536 (Feb.2013)
...There's still more to do but these are very encouraging words in the PR...
"In a phase 1 clinical study of healthy volunteers, ACE-536 produced a dose-dependent increase in red blood cells and hemoglobin levels. "
http://www.checkorphan.org/grid/news...stic-syndromes
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30% ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
|